B of A Securities Maintains Neutral on 10x Genomics, Lowers Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Derik De Bruin maintains a Neutral rating on 10x Genomics (TXG) and lowers the price target from $45 to $36.
May 01, 2024 | 5:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B of A Securities has maintained a Neutral rating on 10x Genomics and reduced the price target from $45 to $36.
The reduction in price target by B of A Securities reflects a negative outlook on the stock's short-term price potential, likely leading to a decrease in investor confidence and a potential short-term decline in TXG's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100